These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30497978)

  • 1. The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase.
    Fog CK; Zago P; Malini E; Solanko LM; Peruzzo P; Bornaes C; Magnoni R; Mehmedbasic A; Petersen NHT; Bembi B; Aerts JFMG; Dardis A; Kirkegaard T
    EBioMedicine; 2018 Dec; 38():142-153. PubMed ID: 30497978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
    Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
    SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of the proteostasis network of plant cells promotes the post-endoplasmic reticulum trafficking of recombinant mutant (L444P) human β-glucocerebrosidase.
    Babajani G; Kermode AR
    Plant Signal Behav; 2014; 9(3):e28714. PubMed ID: 24713615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease.
    Jian J; Tian QY; Hettinghouse A; Zhao S; Liu H; Wei J; Grunig G; Zhang W; Setchell KDR; Sun Y; Overkleeft HS; Chan GL; Liu CJ
    EBioMedicine; 2016 Nov; 13():212-224. PubMed ID: 27789271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction with ERp57 is required for progranulin protection against Type 2 Gaucher disease.
    Liu Y; Zhao X; Jian J; Hasan S; Liu C
    Biosci Trends; 2023 May; 17(2):126-135. PubMed ID: 36889696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of cellular cobalamin metabolism in Gaucher disease.
    Basgalupp SP; Siebert M; Ferreira C; Behringer S; Spiekerkoetter U; Hannibal L; Schwartz IVD
    BMC Med Genet; 2020 Jan; 21(1):12. PubMed ID: 31931749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gaucher disease paradigm: from ERAD to comorbidity.
    Bendikov-Bar I; Horowitz M
    Hum Mutat; 2012 Oct; 33(10):1398-407. PubMed ID: 22623374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol.
    Kalmar B; Lu CH; Greensmith L
    Pharmacol Ther; 2014 Jan; 141(1):40-54. PubMed ID: 23978556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
    Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
    Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ca2+ homeostasis modulation enhances the amenability of L444P glucosylcerebrosidase to proteostasis regulation in patient-derived fibroblasts.
    Wang F; Agnello G; Sotolongo N; Segatori L
    ACS Chem Biol; 2011 Feb; 6(2):158-68. PubMed ID: 21043486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral delivery of a microRNA to Gba to the mouse central nervous system models neuronopathic Gaucher disease.
    Jackson KL; Viel C; Clarke J; Bu J; Chan M; Wang B; Shihabuddin LS; Sardi SP
    Neurobiol Dis; 2019 Oct; 130():104513. PubMed ID: 31233883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease.
    Tan YL; Genereux JC; Pankow S; Aerts JM; Yates JR; Kelly JW
    Chem Biol; 2014 Aug; 21(8):967-76. PubMed ID: 25126989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease.
    Ivanova MM; Dao J; Kasaci N; Adewale B; Nazari S; Noll L; Fikry J; Sanati AH; Goker-Alpan O
    PLoS One; 2021; 16(10):e0247211. PubMed ID: 34695170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase.
    Khanna R; Benjamin ER; Pellegrino L; Schilling A; Rigat BA; Soska R; Nafar H; Ranes BE; Feng J; Lun Y; Powe AC; Palling DJ; Wustman BA; Schiffmann R; Mahuran DJ; Lockhart DJ; Valenzano KJ
    FEBS J; 2010 Apr; 277(7):1618-38. PubMed ID: 20148966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unfolded protein response in Gaucher disease: from human to Drosophila.
    Maor G; Rencus-Lazar S; Filocamo M; Steller H; Segal D; Horowitz M
    Orphanet J Rare Dis; 2013 Sep; 8():140. PubMed ID: 24020503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant.
    Babajani G; Tropak MB; Mahuran DJ; Kermode AR
    Mol Genet Metab; 2012 Jul; 106(3):323-9. PubMed ID: 22592100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.
    Yap TL; Gruschus JM; Velayati A; Westbroek W; Goldin E; Moaven N; Sidransky E; Lee JC
    J Biol Chem; 2011 Aug; 286(32):28080-8. PubMed ID: 21653695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HEPES-buffering of bicarbonate-containing culture medium perturbs lysosomal glucocerebrosidase activity.
    van der Lienden MJC; Aten J; Boot RG; van Eijk M; Aerts JMFG; Kuo CL
    J Cell Biochem; 2022 May; 123(5):893-905. PubMed ID: 35312102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease.
    Schmitz M; Alfalah M; Aerts JM; Naim HY; Zimmer KP
    Int J Biochem Cell Biol; 2005 Nov; 37(11):2310-20. PubMed ID: 15982918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2.
    Thomas R; Moloney EB; Macbain ZK; Hallett PJ; Isacson O
    Mol Brain; 2021 Jan; 14(1):16. PubMed ID: 33468204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.